Friedlander, Michael http://orcid.org/0000-0003-3090-795X
Mileshkin, Linda
Lombard, Janine
Frentzas, Sophia
Gao, Bo
Wilson, Michelle
Meniawy, Tarek
Baron-Hay, Sally
Briscoe, Karen http://orcid.org/0000-0002-1491-6920
McCarthy, Nicole
Fountzilas, Christos http://orcid.org/0000-0003-3837-5644
Cervantes, Andres http://orcid.org/0000-0003-3806-3691
Ge, Ruimin
Wu, John
Spira, Alexander
Funding for this research was provided by:
BeiGene, Ltd.
Article History
Received: 24 November 2022
Revised: 1 June 2023
Accepted: 27 June 2023
First Online: 20 July 2023
Competing interests
: MF declares honoraria for advisory boards AstraZeneca, GSK, Incyclix, Lilly, MSD, Novartis, Takeda; consultancy for AstraZeneca, Eisai, Novartis; speaker’s fee and travel from AstraZeneca; speaker’s fees from GSK and ACT genomics; institutional research funding from AstraZeneca, BeiGene, Novartis. JL declares honoraria for advisory boards from AstraZeneca and GSK; financial support for conference attendance: AstraZeneca, GSK, and Novartis. SF declares financial/honoraria: honoraria for advisory board from Akesobio and MSD; financial support for conference attendance from Amgen; institutional research funding from Akesobio, Ambrax, Amgen, AstraZeneca, Aulos, BeiGene, Cullinian, Daiichi Sankyo, Edison Oncology, HaiHe Biopharma, MSD, Takeda, Vivace, and WMS. MW declares Institutional research support from Roche. TM declares honoraria for advisory boards from AstraZeneca, BMS, GSK, MSD, Novartis, Takeda. SBH declares honoraria for advisory boards from AstraZeneca, Eisai, GSK, MSD, Pfizer; speaker fees from Lilly; consultancy for Roche; education travel from Amgen, Novartis. KB declares honoraria for advisory boards/conference attendance from BMS, MSD, Novartis, Pierre Fabre; institutional research funding from BioGene, BMS, Eucure, Lilly, Merck, Regeneron. NM declares honoraria for advisory boards from AstraZeneca, Novartis, Pfizer, Gilead, Roche; financial support for conference from Amgen, Novartis. CF declares institutional research funding from MSD, the National Comprehensive Cancer Network (NCCN) Foundation, the NCCN Oncology Research Program, Pfizer, Taiho Oncology. AC declares institutional research funding from AnHeart, Astellas, Bayer, BeiGene, BMS, FibroGen, Genentech, Lilly, Merck Serono, MSD, Novartis, Roche, Servier, Takeda; advisory board or speaker fees from Amgen, Bayer, Merck Serono, Pierre Fabre, Roche, Servier in the last 5 years. RG and JW declare employment by BeiGene, Ltd. All other authors declare no competing interests.
: Patients voluntarily agreed to participate by giving written informed consent. This study was conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. Ethics Committee: Melbourne Health Human Research Ethics Committee. • NMA Reference Number: HREC/15/MH/334. • eCTN number: CT-2015-CTN-02675-1 v1.
: Not applicable.